HC Wainwright Reiterates Buy Rating for G1 Therapeutics (NASDAQ:GTHX)

G1 Therapeutics (NASDAQ:GTHX)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $9.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 106.42% from the stock’s current price.

GTHX has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 price objective on shares of G1 Therapeutics in a research note on Wednesday. Wedbush reissued an “outperform” rating and issued a $5.00 price target (up from $4.00) on shares of G1 Therapeutics in a research note on Wednesday, February 28th.

G1 Therapeutics Price Performance

Shares of GTHX stock traded up $0.23 during mid-day trading on Thursday, reaching $4.36. The stock had a trading volume of 512,912 shares, compared to its average volume of 1,252,248. G1 Therapeutics has a 12-month low of $1.08 and a 12-month high of $5.00. The company has a market cap of $228.07 million, a P/E ratio of -4.57 and a beta of 1.71. The business has a 50-day simple moving average of $3.85 and a 200 day simple moving average of $3.05. The company has a current ratio of 3.87, a quick ratio of 3.45 and a debt-to-equity ratio of 1.46.

G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings results on Wednesday, May 1st. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). G1 Therapeutics had a negative net margin of 58.13% and a negative return on equity of 106.04%. The firm had revenue of $14.48 million during the quarter, compared to analysts’ expectations of $15.21 million. During the same quarter in the prior year, the business earned ($0.53) EPS. On average, sell-side analysts anticipate that G1 Therapeutics will post -0.64 earnings per share for the current year.

Insider Activity

In other news, insider Rajesh Malik sold 28,600 shares of G1 Therapeutics stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $4.62, for a total value of $132,132.00. Following the transaction, the insider now directly owns 169,938 shares of the company’s stock, valued at approximately $785,113.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 8.23% of the company’s stock.

Institutional Investors Weigh In On G1 Therapeutics

Several hedge funds have recently modified their holdings of the stock. Raymond James & Associates raised its holdings in shares of G1 Therapeutics by 16.9% during the 3rd quarter. Raymond James & Associates now owns 925,776 shares of the company’s stock valued at $1,333,000 after buying an additional 133,662 shares during the period. abrdn plc purchased a new stake in shares of G1 Therapeutics during the 4th quarter valued at about $1,293,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in G1 Therapeutics by 68.3% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 204,200 shares of the company’s stock worth $294,000 after purchasing an additional 82,879 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in G1 Therapeutics during the 3rd quarter worth approximately $189,000. Finally, FinTrust Capital Advisors LLC increased its holdings in G1 Therapeutics by 154,946.2% during the 4th quarter. FinTrust Capital Advisors LLC now owns 100,780 shares of the company’s stock worth $307,000 after purchasing an additional 100,715 shares during the last quarter. 24.21% of the stock is currently owned by hedge funds and other institutional investors.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.